{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:31Z","timestamp":1792782691620,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"This work was supported by the Italian Ministry of Health, Rome, Italy.","award":["Ricerca Corrente IRCCS Funds, Progetto L2 \/11"],"award-info":[{"award-number":["Ricerca Corrente IRCCS Funds, Progetto L2 \/11"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00277-024-05994-4","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T03:23:26Z","timestamp":1726111406000},"page":"4759-4764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term complete remission in a patient with high-risk primary mediastinal B-cell lymphoma and iatrogenic symptomatic bradycardia after only two courses of DA-EPOCH-R followed by chemo-free treatment"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6509-0578","authenticated-orcid":false,"given":"Francesco","family":"Volzone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-6573","authenticated-orcid":false,"given":"Cristina","family":"Becchimanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Crisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarosaria","family":"De Chiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Caronna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarosa","family":"Cuccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8190-361X","authenticated-orcid":false,"given":"Sabrina","family":"Sarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-5313","authenticated-orcid":false,"given":"Domenico","family":"Mallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Cagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7899-3071","authenticated-orcid":false,"given":"Rosaria","family":"De Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-9026","authenticated-orcid":false,"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"5994_CR1","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood.2020008376","volume":"140","author":"KJ Savage","year":"2022","unstructured":"Savage KJ (2022) Primary mediastinal large B-cell lymphoma. Blood 140:955\u2013970. https:\/\/doi.org\/10.1182\/blood.2020008376","journal-title":"Blood"},{"key":"5994_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41408-020-0312-7","volume":"10","author":"H Zhou","year":"2020","unstructured":"Zhou H, Xu-Monette ZY, Xiao L, Strati P, Hagemeister FB, He Y, Chen H, Li Y, Manyam GC, Li Y, Montes-Moreno S, Piris MA, Young KH (2020) Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J 10:49. https:\/\/doi.org\/10.1038\/s41408-020-0312-7","journal-title":"Blood Cancer J"},{"key":"5994_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jtct.2023.10.009","volume":"29","author":"N Gulati","year":"2023","unstructured":"Gulati N, Giulino-Roth L (2023) Relapsed\/Refractory primary Mediastinal B-cell lymphoma: where do we stand ? Transpl Cell Ther 29:649\u2013650. https:\/\/doi.org\/10.1016\/j.jtct.2023.10.009","journal-title":"Transpl Cell Ther"},{"key":"5994_CR4","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1182\/blood.2019002067","volume":"134","author":"B Chapuy","year":"2019","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Wienand K, Kamburov A, Griffin GK, Chen PH, Lako A, Redd RA, Cote CM, Ducar MD, Thorner AR, Rodig SJ, Getz G, Shipp MA (2019) Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood 134:2369\u20132382. https:\/\/doi.org\/10.1182\/blood.2019002067","journal-title":"Blood"},{"key":"5994_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1200\/JCO.23.01053","volume":"42","author":"D Noerenberg","year":"2024","unstructured":"Noerenberg D, Briest F, Hennch C, Yoshida K, Hablesreiter R, Takeuchi Y, Ueno H, Staiger AM, Ziepert M, Asmar F, Locher BN, Toth E, Weber T, Amini RM, Klapper W, Bouzani M, Poeschel V, Rosenwald A, Held G, Campo E, Ishaque N, Stamatopoulos K, Kanellis G, Anagnostopoulos I, Bullinger L, Goldschmidt N, Zinzani PL, B\u00f6d\u00f6r C, Rosenquist R, Vassilakopoulos TP, Ott G, Ogawa S, Damm F (2024) Genetic characterization of primary Mediastinal B-Cell Lymphoma: Pathogenesis and patient outcomes. J Clin Oncol 42:452\u2013466. https:\/\/doi.org\/10.1200\/JCO.23.01053","journal-title":"J Clin Oncol"},{"key":"5994_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood.2022019340","volume":"142","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Garcia-Sancho AM, Christian B, Gulbas Z, \u00d6zcan M, Perini GF, Ghesquieres H, Shipp MA, Thompson S, Chakraborty S, Marinello P, Armand P (2023) Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood 142:141\u2013145. https:\/\/doi.org\/10.1182\/blood.2022019340","journal-title":"Blood"},{"key":"5994_CR7","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1182\/bloodadvances.2023010254","volume":"7","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Lisano J, Wen R, Akyol A, Moskowitz AJ (2023) Nivolumab combined with brentuximab vedotin for R\/R primary mediastinal large B-cell lymphoma: a 3-year follow-up. Blood Adv 7:5272\u20135280. https:\/\/doi.org\/10.1182\/bloodadvances.2023010254","journal-title":"Blood Adv"},{"key":"5994_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13027-021-00376-1","volume":"16","author":"G Marcacci","year":"2021","unstructured":"Marcacci G, Fiorentino G, Volzone F, Falcone U, Parrella R, Donnarumma D, D\u2019Ovidio S, Annunziata A, Micallo G, Portella G, De Chiara A, De Filippi R, Crisci S, Pinto A (2021) Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to Rituximab. Infect Agent Cancer 16:38. https:\/\/doi.org\/10.1186\/s13027-021-00376-1","journal-title":"Infect Agent Cancer"},{"key":"5994_CR9","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2018-05-851154","volume":"132","author":"A Mottok","year":"2018","unstructured":"Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM (2018) Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood 132:2401\u20132405. https:\/\/doi.org\/10.1182\/blood-2018-05-851154","journal-title":"Blood"},{"key":"5994_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1634\/theoncologist.2011-0275","volume":"17","author":"TP Vassilakopoulos","year":"2012","unstructured":"Vassilakopoulos TP, Pangalis GA, Katsigiannis A, Papageorgiou SG, Constantinou N, Terpos E, Zorbala A, Vrakidou E, Repoussis P, Poziopoulos C, Galani Z, Dimopoulou MN, Kokoris SI, Sachanas S, Kalpadakis C, Dimitriadou EM, Siakantaris MP, Kyrtsonis MC, Dervenoulas J, Dimopoulos MA, Meletis J, Roussou P, Panayiotidis P, Beris P, Angelopoulou MK (2012) Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 17:239\u2013249. https:\/\/doi.org\/10.1634\/theoncologist.2011-0275","journal-title":"Oncologist"},{"key":"5994_CR11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3324\/haematol.2023.283446","volume":"109","author":"MR Cook","year":"2024","unstructured":"Cook MR, Williams LS, Dorris CS, Luo Y, Makambi K, Dunleavy K (2024) Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients. Haematologica 109:846\u2013856. https:\/\/doi.org\/10.3324\/haematol.2023.283446","journal-title":"Haematologica"},{"key":"5994_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40264-021-01132-5","volume":"45","author":"J Tamargo","year":"2022","unstructured":"Tamargo J, Caballero R, Delp\u00f3n E (2022) Cancer chemotherapy-induced sinus bradycardia: a narrative review of a forgotten adverse effect of cardiotoxicity. Drug Saf 45:101\u2013126. https:\/\/doi.org\/10.1007\/s40264-021-01132-5","journal-title":"Drug Saf"},{"key":"5994_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/bmt.2009.318","volume":"45","author":"M Musso","year":"2010","unstructured":"Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, Di Bartolomeo P, Crescimanno A, Perrone T, Pinto A (2010) Fotemustine plus Etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transpl 45:1147\u20131153. https:\/\/doi.org\/10.1038\/bmt.2009.318","journal-title":"Bone Marrow Transpl"},{"key":"5994_CR14","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.bbmt.2018.06.009","volume":"24","author":"S Vardhana","year":"2018","unstructured":"Vardhana S, Hamlin PA, Yang J, Zelenetz A, Sauter CS, Matasar MJ, Ni A, Yahalom J, Moskowitz CH (2018) Outcomes of relapsed and refractory primary Mediastinal (Thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transpl 24:2133\u20132138. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.009","journal-title":"Biol Blood Marrow Transpl"},{"key":"5994_CR15","doi-asserted-by":"publisher","first-page":"5253","DOI":"10.1007\/s00210-024-02955-6","volume":"397","author":"C Ke","year":"2024","unstructured":"Ke C, Chen M, Huang Y, Chen Y, Lin C, Huang P (2024) Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA adverse event reporting System (FAERS) database. Naunyn Schmiedebergs Arch Pharmacol 397:5253\u20135264. https:\/\/doi.org\/10.1007\/s00210-024-02955-6","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5994_CR16","doi-asserted-by":"publisher","unstructured":"Long P, Li S, Pan L, Wang Y, Chen W, Wang X (2024) Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database. https:\/\/doi.org\/10.1007\/s00210-024-02955-6. Front Pharmacol15:1378010","DOI":"10.1007\/s00210-024-02955-6"},{"key":"5994_CR17","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.amjmed.2021.05.026","volume":"134","author":"H Essa","year":"2021","unstructured":"Essa H, Wright DJ, Dobson R, Lip GYH (2021) Chemotherapy-Induced Arrhythmia - Underrecognized and Undertreated. Am J Med 134:1224\u20131231. https:\/\/doi.org\/10.1016\/j.amjmed.2021.05.026","journal-title":"Am J Med"},{"key":"5994_CR18","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S1470-2045(22)00221-2","volume":"23","author":"EL Giraud","year":"2022","unstructured":"Giraud EL, Ferrier KRM, Lankheet NAG, Desar IME, Steeghs N, Beukema RJ, van Erp NP, Smolders EJ (2022) The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. Lancet Oncol 23:e406\u2013e415. https:\/\/doi.org\/10.1016\/S1470-2045(22)00221-2","journal-title":"Lancet Oncol"},{"key":"5994_CR19","doi-asserted-by":"publisher","first-page":"114912","DOI":"10.1016\/j.biopha.2023.114912","volume":"164","author":"A Mascolo","year":"2023","unstructured":"Mascolo A, Sportiello L, Rafaniello C, Donniacuo M, Ruggiero D, Scisciola L, Barbieri M, Rossi F, Paolisso G, Capuano A (2023) Do immune checkpoint inhibitors share the same pharmacological feature in the risk of cardiac arrhythmias? Biomed Pharmacother 164:114912. https:\/\/doi.org\/10.1016\/j.biopha.2023.114912","journal-title":"Biomed Pharmacother"},{"key":"5994_CR20","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1182\/bloodadvances.2023011169","volume":"27","author":"V Camus","year":"2023","unstructured":"Camus V, Viailly PJ, Drieux F, Veresezan EL, Sesques P, Haioun C, Durot E, Patey M, Rossi C, Martin L, Rainville V, Bohers E, Ruminy P, Penther D, Kaltenbach S, Bruneau J, Paillassa J, Tournilhac O, Willaume A, Antier C, Lazarovici J, L\u00e9v\u00eaque E, Decazes P, Becker S, Tonnelet D, Berriolo-Riedinger A, Gaulard P, Tilly H, Molina TJ, Traverse-Glehen A, Jardin F (2023) High PDL1\/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma. Blood Adv 27:7331\u20137745. https:\/\/doi.org\/10.1182\/bloodadvances.2023011169","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05994-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05994-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05994-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T04:29:38Z","timestamp":1730694578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05994-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["5994"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05994-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the Institutional Review Boards-approved LYMRO-22 study (20\/22 OSS; date of approval 27 July 2022, Istituto Pascale, Italy). Patients enrolled into the LYMRO-22 allow the use of anonymized registered clinical data for scientific purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Informed consent has been obtained from the patient for clinical. data collection, elaboration and publication of the present report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"FV declares honoraria from Hoffmann-La Roche AG irrelevant to the present research; AP declares honoraria from Hoffmann-La Roche AG, Incyte, Merck Sharp and Dohme, Bristol-Meyers Squibb and Ely-Lilly all irrelevant to the present research. AnC declares honoraria from Takeda, irrelevant to the present research. All the other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}}]}}